Search Results - "Schafhausen, P."

Assessment of imatinib as first-line treatment of chronic myeloid leukemia: 10-year survival results of the randomized CML study IV and impact of non-CML determinants by Hehlmann, R, Lauseker, M, Saußele, S, Pfirrmann, M, Krause, S, Kolb, H J, Neubauer, A, Hossfeld, D K, Nerl, C, Gratwohl, A, Baerlocher, G M, Heim, D, Brümmendorf, T H, Fabarius, A, Haferlach, C, Schlegelberger, B, Müller, M C, Jeromin, S, Proetel, U, Kohlbrenner, K, Voskanyan, A, Rinaldetti, S, Seifarth, W, Spieß, B, Balleisen, L, Goebeler, M C, Hänel, M, Ho, A, Dengler, J, Falge, C, Kanz, L, Kremers, S, Burchert, A, Kneba, M, Stegelmann, F, Köhne, C A, Lindemann, H W, Waller, C F, Pfreundschuh, M, Spiekermann, K, Berdel, W E, Müller, L, Edinger, M, Mayer, J, Beelen, D W, Bentz, M, Link, H, Hertenstein, B, Fuchs, R, Wernli, M, Schlegel, F, Schlag, R, de Wit, M, Trümper, L, Hebart, H, Hahn, M, Thomalla, J, Scheid, C, Schafhausen, P, Verbeek, W, Eckart, M J, Gassmann, W, Pezzutto, A, Schenk, M, Brossart, P, Geer, T, Bildat, S, Schäfer, E, Hochhaus, A, Hasford, J

“…Chronic myeloid leukemia (CML)-study IV was designed to explore whether treatment with imatinib (IM) at 400 mg/day ( n =400) could be optimized by doubling the…”
Get full text

A randomised phase II trial of hydroxychloroquine and imatinib versus imatinib alone for patients with chronic myeloid leukaemia in major cytogenetic response with residual disease by Horne, G. A., Stobo, J., Kelly, C., Mukhopadhyay, A., Latif, A. L., Dixon-Hughes, J., McMahon, L., Cony-Makhoul, P., Byrne, J., Smith, G., Koschmieder, S., BrÜmmendorf, T. H., Schafhausen, P., Gallipoli, P., Thomson, F., Cong, W., Clark, R. E., Milojkovic, D., Helgason, G. V., Foroni, L., Nicolini, F. E., Holyoake, T. L., Copland, M.

“…In chronic-phase chronic myeloid leukaemia (CP-CML), residual BCR-ABL1 + leukaemia stem cells are responsible for disease persistence despite TKI. Based on in…”
Get full text

The current role of systemic chemotherapy in the primary treatment of head and neck cancer by Busch, C.-J, Tribius, S, Schafhausen, P, Knecht, R

“…Highlights • Interpreting studies including ICT in HNSCC is complicated by several protocols, treatment settings and different endpoints. • ICT has a role in…”
Get full text

Cisplatin, 5-fluorouracil, and cetuximab (PFE) with or without cilengitide in recurrent/metastatic squamous cell carcinoma of the head and neck: results of the randomized phase I/II ADVANTAGE trial (phase II part) by Vermorken, J.B., Peyrade, F., Krauss, J., Mesía, R., Remenar, E., Gauler, T.C., Keilholz, U., Delord, J.P., Schafhausen, P., Erfán, J., Brümmendorf, T.H., Iglesias, L., Bethe, U., Hicking, C., Clement, P.M.

“…Recurrent and/or metastatic squamous cell carcinoma of the head and neck (R/M-SCCHN) overexpresses &agr;v&bgr;5 integrin. Cilengitide selectively inhibits…”
Get full text

Prevalence, clonal dynamics and clinical impact of TP53 mutations in patients with myelodysplastic syndrome with isolated deletion (5q) treated with lenalidomide: results from a prospective multicenter study of the german MDS study group (GMDS) by Mossner, M, Jann, J-C, Nowak, D, Platzbecker, U, Giagounidis, A, Götze, K, Letsch, A, Haase, D, Shirneshan, K, Braulke, F, Schlenk, R F, Haferlach, T, Schafhausen, P, Bug, G, Lübbert, M, Ganser, A, Büsche, G, Schuler, E, Nowak, V, Pressler, J, Obländer, J, Fey, S, Müller, N, Lauinger-Lörsch, E, Metzgeroth, G, Weiß, C, Hofmann, W-K, Germing, U, Nolte, F

Get full text

Impact of single-room contact precautions on hospital-acquisition and transmission of multidrug-resistant Escherichia coli: a prospective multicentre cohort study in haematological and oncological wards by Biehl, L.M., Higgins, P., Wille, T., Peter, K., Hamprecht, A., Peter, S., Dörfel, D., Vogel, W., Häfner, H., Lemmen, S., Panse, J., Rohde, H., Klupp, E.-M., Schafhausen, P., Imirzalioglu, C., Falgenhauer, L., Salmanton-García, J., Stecher, M., Vehreschild, J.J., Seifert, H., Vehreschild, M.J.G.T.

“…Colonization and infection with third-generation cephalosporin-resistant Escherichia coli (3GCR-EC) are frequent in haematological and oncological patients. In…”
Get full text

Results of a multicenter prospective phase II trial investigating the safety and efficacy of lenalidomide in patients with myelodysplastic syndromes with isolated del(5q) (LE-MON 5) by Schuler, E, Giagounidis, A, Haase, D, Shirneshan, K, Büsche, G, Platzbecker, U, Nolte, F, Götze, K, Schlenk, R F, Ganser, A, Letsch, A, Braulke, F, Lübbert, M, Bug, G, Schafhausen, P, Bacher, U, Gattermann, N, Wulfert, M, Haas, R, Germing, U

Get full text

Treatment of head and neck squamous cell carcinoma recurrences and distant metastases : Highlights of the 2019 ASCO Meeting by Zech, H B, Laban, S, Schafhausen, P, Bussmann, L, Betz, C, Busch, C-J

“…The contributions presented at this year's ASCO conference on treatment of recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) focused on…”
Get full text

Pomalidomide in myeloproliferative neoplasm-associated myelofibrosis by Schlenk, R F, Stegelmann, F, Reiter, A, Jost, E, Gattermann, N, Hebart, H, Waller, C, Hochhaus, A, Platzbecker, U, Schafhausen, P, Blau, I W, Verbeek, W, Heidel, F H, Werner, M, Kreipe, H, Teleanu, V, Benner, A, Döhner, H, Grießhammer, M, Döhner, K

“…Myeloproliferative neoplasm (MPN)-associated myelofibrosis is a MPN characterized by bone marrow fibrosis, cytopenias, splenomegaly and constitutional…”
Get full text

A randomized phase II study comparing the efficacy and safety of the glyco-optimized anti-EGFR antibody tomuzotuximab against cetuximab in patients with recurrent and/or metastatic squamous cell cancer of the head and neck – the RESGEX study by Klinghammer, K., Fayette, J., Kawecki, A., Dietz, A., Schafhausen, P., Folprecht, G., Rottey, S., Debourdeau, P., Lavernia, J., Jacobs, A., Ahrens-Fath, I., Dietrich, B., Baumeister, H., Zurlo, A., Ochsenreither, S., Keilholz, U.

“…The aim of the RESGEX study was to compare the efficacy and safety of the anti-epidermal growth factor receptor (anti-EGFR) antibody tomuzotuximab against…”
Get full text

P828: NORMALIZATION OF HEMATOLOGIC AND HEALTH‐RELATED QUALITY OF LIFE MARKERS IN PATIENTS WITH PAROXYSMAL NOCTURNAL HEMOGLOBINURIA TREATED WITH PEGCETACOPLAN AND BASELINE HEMOGLOBIN AT OR ABOVE 10 G/DL by Panse, J., Daguindau, N., Okuyama, S., Peffault de Latour, R., Schafhausen, P., Straetmans, N., Al‐Adhami, M., Ajayi, T., Persson, E., Yeh, M., Wong, R.

Get full text

Nasopharynxkarzinom – ein aktueller Überblick über eine spezielle Tumorentität by Zech, H. B., Matnjani, G., Schafhausen, P., Betz, C. S.

“…Zusammenfassung Karzinome des Nasopharynx stellen eine spezielle Entität dar, die sich von anderen Kopf-Hals-Tumoren in ihrer Ätiologie, Tumorbiologie,…”
Get full text

Induction chemotherapy followed by radiochemotherapy for locally advanced head and neck cancer as an individual treatment approach—Feasibility, safety and retrospective survival analysis in twenty‐three patients by Busch, C.‐J., Girke, J., Tribius, S., Bussmann, L., Knecht, R., Schafhausen, P., Lörincz, B.B., Münscher, A.

Get full text

P1055: CLINICAL AND GENETIC RESULTS OF THE PHASE IB/II TRIAL MPNSG‐0212: RUXOLITINIB PLUS POMALIDOMIDE IN MYELOFIBROSIS WITH ANEMIA by Stegelmann, F., Jahn, E., Koschmieder, S., Heidel, F., Hochhaus, A., Hebart, H., Isfort, S., Reiter, A., Bangerter, M., Waller, C. F., Wolleschak, D., Scheid, C., Göthert, J., Schafhausen, P., Kindler, T., Radsak, M. P., Gattermann, N., Möhle, R., Bubnoff, N., Schrade, A., Brümmendorf, T., Döhner, H., Griesshammer, M., Döhner, K.

Get full text

120 RESULTS OF THE MULTICENTER, PHASE II STUDY OF THE SAFETY OF LENALIDOMIDE MONOTHERAPY IN PATIENTS WITH MYELODYSPLASTIC SYNDROMES (MDS) ASSOCIATED WITH AN ISOLATED DEL(5Q) by Schuler, E, Schemenau, J, Giagounidis, A, Haase, D, Büsche, G, Platzbecker, U, Nolte, F, Götze, K, Schlenk, R.F, Ganser, A, Letsch, A, Lübbert, M, Schafhausen, P, Bug, G, Germing, U

Get full text

Evaluation of BM cytomorphology after allo-SCT in patients with MDS by Christopeit, M, Ocheni, S, Haferlach, T, Miersch, K, Zabelina, T, Klyuchnikov, E, Binder, M, Ayuk, F, Schafhausen, P, Zander, A R, Bokemeyer, C, Kröger, N, Bacher, U

Get full text

Evaluation of BM cytomorphology after allo-SCT in patients with AML by Christopeit, M, Miersch, K, Klyuchnikov, E, Haferlach, T, Binder, M, Zabelina, T, Ayuk, F, Schafhausen, P, Zander, A R, Bokemeyer, C, Kröger, N, Bacher, U

“…Estimation of relapse risk in AML after allo-SCT is critical. The negative impact of increased blast count post transplant is widely accepted. Here, we studied…”
Get full text

Therapy of recurrent or metastatic head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2014 by Zeller, N, Busch, C-J, Schafhausen, P, Knecht, R, Möckelmann, N

“…The treatment of patients with recurrent or metastatic head and neck squamous cell carcinoma (R/M-HNSCC) requires exceptional interdisciplinary cooperation…”
Get full text

Therapy of recurrent and metastatic squamous cell carcinoma of the head and neck : highlights of the ASCO Meeting 2013 by Hezel, M, Kurzweg, T, Münscher, A, Schafhausen, P, Knecht, R

“…In many cases squamous cell carcinoma of the head and neck is already in an advanced stage when initially diagnosed. Despite definitive treatment,…”
Get full text

The most important study results of primary chemoradiation for head and neck squamous cell carcinoma : highlights of the ASCO Meeting 2013 by Münscher, A, Busch, C-J, Schafhausen, P, Tribius, S, Knecht, R

“…Primary concomitant and sequential chemoradiation is a commonly used therapeutic strategy for head and neck squamous cell carcinoma. At the annual meeting of…”
Get full text